retatrutide and tirzepatide vs. Tirzepatide: The Next-Gen GLP-1 Showdown Retatrutide vs Semaglutide and Tirzepatide:

PMID: 31624689

A.VeggeA.MaarbjergS

GLP-1 agonists address multiple aspects of type 2 diabetes - reducing blood sugar, promoting weight loss, and providing cardiovascular protection - making them a strong option for thorough diabetes management

Summary Heart palpitations are relatively uncommon among semaglutide users, with one source reporting about 1% and broader summaries noting cardiovascular side effects under 5%, so most patients will not develop persistent arrhythmias

This precision medicine approach transforms GLP-1 therapy from a standard treatment into a truly personalized intervention

This difference helped establish semaglutide as an important option in medical weight management